Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3109)	12/28/2010 1:02:11 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

OPK also has had its ups and downs today, but it is now unchanged with volume of 287Ks still below its ADV.<g> bigcharts.marketwatch.com The stock has been down in the last week,but the CEO has continued his steady accumulation.<g> finance.yahoo.com The slides from its presentation at Lazard, were commented in the YHOO Message Boards.<g> messages.finance.yahoo.com As presented on those slides, it seems that OPK has what appears to be some good potential for further development.<g> files.shareholder.com Besides its Rolapitant that it acquired from SGP in order that it could merge with MRK and that seems to have potential for treatment of nausea and vomiting, OPK also has acquired companies in Chile and Mexico as well as some 'interesting' technologies in Molecular Diagnostics and Vaccines.<g> opko.com In February, the stock had a spike after announcing some data about its test for AD. <g> pdonlineresearch.org OPKO is no longer an ophthalmology focused company, and it has expanded its field of interest. Its CEO has a good previous record, with Key Pharmaceuticals, IVAX, TEVA, etc. Another of his holdings, PBTH also seems to have good potential with its CPT technology.<g> prolor-biotech.com There is no ACTAY for OPK. But I will keep a TT at $5 <g> Disclosure: I remain long on OPK and also bought a few more shares today.<g> Bernard